SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced that Germany’s National Genome Research Network (NGFN) has selected Illumina’s Infinium® HumanCNV370-Duo, HumanHap300-Duo, and HumanHap550 BeadChips to conduct one of the world’s largest genetic research projects to date. Scientists will genotype 8,000 patients and controls using Illumina’s tools to investigate genetic variations to better understand underlying causes of 25 complex diseases. Diseases to be studied using Illumina’s tools include several mental health diseases such as Bipolar disease and Schizophrenia, in addition to Parkinson’s disease, Alzheimer’s disease, Alcohol addiction, Inflammatory Bowel Disease, and Psoriasis.
